Transition to the EU Clinical Trials Regulation: Trick or treat? - Volume 32, Issue

The etiquette in clinical trial research requires companies to respect rules and to be precise and accurate. The new EU Clinical Trials Regulation 536/2014 (EU CTR) pushes companies and health authorities one step further – to be more flexible and…

Out On Our Own - Volume 24, Issue

Editorial In this issue, Satyendra Shenoy, a member of a few years from Mumbai tells us about the tribulations – if not trials – of realising his lifelong ambition to settle in Germany. What eventually made this possible was discovering, as a…

How can we maximise patient engagement with Plain Language Summary of Publication articles (PLSPs)? A publisher’s perspective - Volume 33, Issue

Plain Language Summary of Publication articles (PLSPs) are aimed at non-specialist audiences, using non-technical/jargon-free and easy to understand language to provide summaries of publications. The introduction of PLSPs has added to the growing…

EMA Foreword - Volume 32, Issue

The EU Clinical Trials Regulation and its much-anticipated benefits: Foreword from the European Medicines Agency The year 2022 signalled the beginning of a new way of handling clinical trials in Europe, with the implementation of the EU Clinical…

Optimizing the value of regulatory writers - Volume 31, Issue

An expanding need for clinical documentation and regulatory health authority interactions during drug development has drawn increased attention to the role of the regulatory medical writer. This role is frequently misunderstood and poorly…

The Crofter: Sustainable Communications - Volume 32, Issue

Editorial Kimi Uegaki (section editor) Medical Writing. 2023(3):105. Why environmental sustainability requires us to focus on our handprint – and write about it Egid van Bree (author) Environmental sustainability has gained increasing attention…

News from the EMA - Volume 30, Issue

First CAR-T cell medicine for mantle cell lymphoma October  16, 2020 – The EMA has recommended granting a conditional marketing authorisation in the EU for Tecartus (autologous anti-CD19-transduced CD3+ cells) for the treatment of adult patients…

News from the EMA - Volume 30, Issue

February 26, 2021 – EMA has recommended granting a marketing authorisation in the European Union (EU) for the first treatment that can be given orally to patients with certain types of spinal muscular atrophy (SMA), a rare and often fatal genetic…

Pharmaceutical clinical trials transparency and privacy - Volume 29, Issue

With the introduction of new clinical trial transparency regulations around the world, transparency functions have had to adapt to a range of reporting requirements. In 2007, the FDA Amendments Act (FDAAA) established requirements for trial sponsors…

Good Writing Practice - Volume 30, Issue

Grammatical misagreement in tense

I – Present, present perfect

Introduction

Each of the sections of a journal article contains anticipated conceptual components, which can be expressed by a specific verb tense for the perspective of time and the d…